The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.
The goal of the PROMISE research study is to determine clinical/genomic alterations present in individuals with MGUS and SMM, who are diagnosed through screening of a high-risk population. We also seek to determine clinical/genomic/epigenetic and immune environmental predictors of progression to multiple myeloma in patients with MGUS and SMM.
Study Type
OBSERVATIONAL
Enrollment
30,000
Collection of blood sample from participants
Dana Farber Cancer Institute
Boston, Massachusetts, United States
RECRUITINGTime to progression (TTP) from MGUS/SMM to overt multiple myeloma.
Progression to symptomatic multiple myeloma
Time frame: 15 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.